WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

Determination of bioequivalence to the Reference Listed Drug is essential for approval of an Abbreviated New Drug Application (ANDA).FDA has advised NRx in written correspondence that it has not identified any bioequivalence deficiencies in the Company's Preservative-Free Ketamine product. This communication is deemed preliminary until final supervisory review.NRx continues to anticipate an FDA GDUFA decision on its ANDA application in Summer 2026 as previously announced.The ANDA process is focused on offering a preservative-free alternative in the existing ketamine market through the FDA Office of Generic Drugs and is separate from NRx's path to a New Drug Application to use ketamine in the

NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research.Minutes are consistent with previously announced oral guidance outlining a path to New Drug Approval of NRX-100 for a broadened indication of treating depression, including patients with suicidality.FDA confirmed willingness to review existing Adequate and Well Controlled Clinical Trial data as Substantial Evidence of Efficacy together with Real World Evidence from Osmind, Inc. as confirmatory evidence of efficacy.No additional clinical trials were requested.Company intends to sumbit its New D

Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical leadership by physicians trained at Harvard, Johns Hopkins, Georgetown, and other leading Universities.Now accepting patients, call 1-833-4HOPETMS WEST PALM BEACH, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), today announced the opening of its Palm Beach, FL clinic location dedicated to the treatment of Depression and PTSD with an interventional psychiatry approach that includes ketamine1 and other neuroplastic drugs, transcranial magnetic stimulation (TMS), and hyperbaric oxygen,

Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

NRx together with Osmind, Inc. conducted an in-person meeting attended by leadership of the FDA Division of Psychiatry Products and leadership of the FDA Center for Drug Evaluation and Research (CDER)Oral guidance received at the meeting provides a path to filing an application for New Drug Approval of NRX-100 under already-awarded Fast Track Designation based on existing clinical trial data and Real World EvidenceBased on the guidance, NRx will seek a broader proposed indication for NRX-100 to serve patients with treatment-resistant depression who may have suicidality rather than only the subset with suicidality WILMINGTON, Del., Feb. 17, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, I

WILMINGTON, Del., Jan. 16, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) (the "Company"), a clinical-stage biopharmaceutical company, today announced that it will hold its annual meeting of stockholders (the "2025 Annual Meeting") on March 23, 2026 at 10:00 a.m. Eastern Time, in virtual-only format at https://www.cstproxy.com/nrxpharma/2026, and any adjournments or postponements thereof. The Company's Board of Directors (the "Board") also set a record date of February 12, 2026 entitling stockholders of record as of such date to notice of and to vote at the 2025 Annual Meeting. The Company will provide additional details regarding the exact time and matters to be voted o

NRX-100 (preservative-free ketamine) has been granted Fast Track Designation by FDA for treatment of suicidal ideation in patients with Depression and Bipolar Depression.Real-world evidence, consistent with FDA guidance, is supplied and generated by Osmind using its nationwide electronic medical records-derived dataset.Previously presented preliminary analysis of a 20,000 patient subset documented rapid resolution of depression and suicidality with initiation of intravenous ketamine.Analyses suggested that clinical response to intravenous ketamine is consistent with prior randomized trial data and compares favorably to currently-approved products.Results from an upcoming analysis of the full

Program will integrate existing neurocare clinics with HOPE Therapeutics clinics and will engage the already-installed base of 400+ Apollo® Transcranial Magnetic Stimulation (TMS) machines nationwide.Program will unite common treatment protocols and clinical training with neurocare expertise in neuromodulation technology and NRx Pharmaceuticals neuroplastic drug development program.Pilot program with a state first-responder agency has demonstrated high rates of success in combining TMS, neuroplastic drug treatment, hyperbaric oxygen, and psychotherapy to achieve remission from PTSD and Depression in First Responders.neurocare and NRx look forward to offering an integrated treatment program t

Remaining $5.4 million debt was repaid through strategic equity conversion in common stock with no additional warrants or adjustment provisionsCompany anticipates that Dec 31 balance sheet will reflect no outstanding convertible debtDebt-free balance sheet sets the stage for accelerated growth in 2026 with potential drug approvals and clinic expansions WILMINGTON, Del., Dec. 18, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has repaid the remaining $5.4 million balance sheet debt to Anson Funds, LLC, through equity conversion of common stock. There were no warrants or other repricing mechanisms associa

DEFA14A - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

DEF 14A - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

424B5 - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

PRE 14A - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

EFFECT - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

3 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

3 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

3 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

H.C. Wainwright initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $40.00

BTIG Research initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $18.00

SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

Prof. Brown is a pioneer in Transcranial Magnetic Stimulation (TMS) and serves as current President of the Clinical TMS Society and Editor-in-Chief of the Transcranial Magnetic Stimulation journal.Extensive publication history in the science of neuroplasticity and its relationship to healing depression and PTSD.Unique background in charting a path for forward deployment of TMS with neuroplastic medication to treat depression and PTSD in military personnel, veterans, and first responders. WILMINGTON, Del., March 02, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), a clinical-stage biopharmaceutical company, today announced that it has appointed Prof. Joshua C. Brown, MD, P

Cohen and Associates has more than a decade of leadership in interventional psychiatry and Transcranial Magnetic Stimulation (TMS) Dr. Rebecca Cohen has joined HOPE as Medical DirectorImmediate expansion is planned in Western Florida and Palm BeachAcquisition expected to be accretive to HOPE Therapeutics revenue and EBITDA MIAMI, Oct. 20, 2025 (GLOBE NEWSWIRE) -- HOPE Therapeutics™, Inc. ("HOPE"), an interventional psychiatry network owned by NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), today announced the acquisition of a strategic interest in Cohen and Associates, LLC ("Cohen, LLC") and its incorporation into the HOPE Network. Additionally, Rebecca Cohen, MD has joined HOPE as Medical Dire

WILMINGTON, Del., July 29, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", or the "Company"), today announced that its CEO and Chairman will join a fireside chat at BTIG Virtual Biotechnology Conference on July 29 – 30, 2025. Prof. Jonathan Javitt, MD, MPH will join Prof. Samuel Wilkinson, MD, of the Yale School of Medicine, and  BTIG Research Analyst Dr. Thomas Shrader for a fireside chat to discuss neuroplasticity in the treatment of CNS disorders at 8:00 a.m. EDT on Wednesday, July 30, 2025. Prof. Wilkinson is a widely published psychiat

Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwideKadima is a leading investigative site for CNS and psychedelic research, having served as the lead site in nearly all major trials in this spaceDr. David Feifel, a nationally recognized pioneer in interventional psychiatry to join HOPE as Chief Medical Innovation Officer upon closing Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPEMIAMI, May 13, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ:NRXP), a clinic

WILMINGTON, Del., Jan. 15, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., a development stage medical and technology driven company and wholly owned subsidiary of NRx, today announced the appointment of Mr. Michael Taylor and Ms. Anita Nunes as Member and Observer of its Board of Directors, respectively.  Ms. Nunes is also to be appointed to the Board of Directors of Hope Therapeutics, Inc. Michael Taylor brings over 25 years of experience in global cr

"'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay GuptaDavid Feifel MD PHD, Founder of Kadima, is a global thought leader in the interventional psychiatry fieldKadima Neuropsychiatry Institute identified as planned HOPE Flagship Clinic pending acquisition closingDr. Feifel is expected to join HOPE as Chief Medical Innovation OfficerMIAMI, Jan. 14, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (NASDAQ:NRXP), today alerted investors that Kadima Neuropsychiatry Institute's Founder David Feifel, MD PHD was fea

Anticipated capital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRx Pharmaceutical operations.Purchase of $25 million in Series A Preferred Stock in HOPE Therapeutics (non-dilutive to NRXP shareholders) convertible into 1/3 of fully diluted HOPE Therapeutics equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions.Purchase $2 million in NRx equity, above the most recent closing price, at $2.75 per share. Investor will also purchase 500,000 NRx shares from existing shareholders for $2.75 per shareIn connection with both investments, investor shall receive w

Kadima Neuropsychiatry Institute in La Jolla, CA to serve as flagship for an international network of clinics dedicated to treating depression and PTSDKadima's founder, David Feifel, MD, PhD, Professor Emeritus of Psychiatry at University of California San Diego, a pioneer in advanced interventional treatments for neuropsychiatric conditions such as depression and PTSD, to join Hope as Chief Medical Innovation OfficerKadima is a leading investigative site for CNS and psychedelic research, and has served as the lead site in nearly all major clinical trials in this areaAcquisition expected to be immediately accretive to revenue and EBITDA for NRx MIAMI, Jan. 2, 2025 /PRNewswire/ -- HOPE Therap

Former Inspector General, US Dept. of Health and Human ServicesFormer Assistant US Attorney for the Eastern District of VirginiaNationally recognized attorney in highly regulated industries; healthcare specialistRADNOR, Pa., Dec. 27, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced that Janet Rehnquist has been elected to the Company's Board of Directors where she will chair the compliance and the nominating committees. Ms. Rehnquist is an experienced healthcare lawye

Extensive global pharmaceutical leadership experience in clinical development, operations, and medical affairsFocused psychiatry practice expert in PTSD, Affective Disorders and SchizophreniaProven track record in research as an investigator and academic grant-funded researcher Visiting Scholar at Stanford University, Center for Precision Mental Health and WellnessFormer roles at Boehringer Ingelheim and Pendulum Therapeutics RADNOR, Pa., Dec. 5, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced the appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC,

WILMINGTON, Del., March 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a conference call at 8:00am ET on Tuesday, March 24, 2026. In addition to reviewing the Company's financial results for the fiscal year ended December 31, 2025, the Company will provide an update on the significant progress achieved across its drug development programs and the HOPE Therapeutics clinical network, milestones that bring the Company closer to its founding mission of preventing suicide and transforming the treatment of depression and PTSD to improve the lives of patient

WILMINGTON, Del., Dec. 02, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will host a corporate update conference call on Tuesday, December 2, 2025 at 9:00am ET. The call will provide a corporate update, including recent clinical, regulatory, and operational developments. A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-800-717-1738 or internationally 1-646-307-1865. About NRx P

NRx has refiled its Abbreviated New Drug Application for KETAFREE™ (preservative free ketamine), received supportive correspondence from FDA, and expects Q2 2026 GDUFA date.HOPE Therapeutics is now operating three revenue-generating facilities in Florida and expects six or more by year-end providing neuroplastic drugs, transcranial magnetic stimulation, hyperbaric therapy, and digital therapeutics to treat suicidal depression and PTSD.NRx has secured operating capital anticipated to be sufficient for drug development operations through July 2026. The Company additionally expects to increase revenue from clinical operations.NRx received FDA grant of Fast Track Designation for NRX-100 in the t

WILMINGTON, Del., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2025 financial results before the market opens on Monday, November 17, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call at 8:30am ET the same day. The call will provide a corporate and financial update and go forward operational plans.   A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events. Participants tha

NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need.Represents an approximately 10-fold expansion of the addressable market to 13 million Americans, compared to the original Fast Track Designation issued in 2017 for bipolar depression alone. The Designation letter contains a specific finding that NRX-100 addresses an "unmet medical need." This is a specific qualifying requirement for the Commissioner's National Priority Voucher Program.Filing of Commissioner's National Priority Voucher application for intravenous ketamine (NRX-100).Subm

Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Tuesday, August 19, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.  The Company will host a conference call the following morning at 8:00am ET, Wednesday August 20, 2025. The Company requires addi

WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Thursday, August 14, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call at 4:30pm ET the same day. The call will provide a corporate and financial update, with a focus on recent regulatory events, regulatory strategy and go forward operational plans.   A live webcast of the conference call will be available on the Co

Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicidal depression, PTSD, and related conditions. Clinic acquisition financing is at the HOPE Therapeutics level and non-dilutive to NRXP shareholdersIn January 2025 completed the third tranche of a convertible note offering and registered direct equity offering to an institutional investor on favorable terms to the Company; expected to provide sufficient cash to support operations through the end of 2025. Deployed capital to meet the objectives listed belowNRX-100 (preservative-free IV ketamine) pla

WILMINGTON, Del., May 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2025 financial results after the market closes on Thursday, May 15, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30pm ET the same day. A live webcast of the conference call will be av

Investment to support initiation of HOPE's network of clinics to treat suicidal depression and PTSD with ketamine, TMS and other modalities MIAMI, April 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (NASDAQ:NRXP), today announced signing of a term sheet with a global medical device manufacturer, as anticipated in the Company's recently filed annual report. The investor shares HOPE's vision of providing comprehensive interventional psychiatry treatments to patients around the world.